Moderna said on August 23 that it has grabbed Japanese regulatory approval for an updated monovalent formulation of its COVID-19 mRNA vaccine Spikevax that targets the JN.1 variant of the novel coronavirus.The updated jab is intended for use in COVID-19…
To read the full story
Related Article
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





